Newsroom

The latest news and updates from Oncopeptides

In the spotlight

Oncopeptides publishes the 2025 Annual Report

Latest press releases

Oncopeptides publishes the 2025 Annual Report

Annual General Meeting in Oncopeptides

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

Number of shares and votes in Oncopeptides

Outcome in Oncopeptides’ rights issue

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Latest news

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

Sofia Heigis presented and interviewed at Stockholm Corporate Finance Life Science Days

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

CEO Sofia Heigis presents Oncopeptides at Aktiespararna

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Biostock: presentation and interview with Sofia Heigis

February 20, 2026

Oncopeptides CEO Sofia Heigis interviewed by Redeye about Q4 and the new share issue

April 29, 2026

The final Oncopeptalks

In the latest, and “final”, Oncopeptalks, Sofia covers, among other things, congress season, and David provides some updates from the communications side – including that Oncopeptalks will take on a new shape in the future.

Upcoming events

7th European Myeloma Network Meeting

Clarion Congress Hotel, Prague, Czech Republic

12th World Congress on Controversies in Multiple Myeloma (COMy)

Paris, France & Online

EHA Congress 2026

The European Hematology Association (EHA)

Stockholm, Sweden